Evidence map›Paper›PMID 42569219›Full record

ArticleGastro hep advances2026

Colonoscopic or Capsule Fecal Microbiota Transplantation for Recurrent

Dina Belhasan, Nataliia Kuchma, Monika Fischer, Jessica R Allegretti, Colleen R Kelly, Alexander Khoruts, Byron P Vaughn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dina BelhasanDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota.
Nataliia KuchmaDivision of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota.
Monika FischerDivision Gastroenterology and Hepatology, Indiana University Health, Indianapolis, Indiana.
Jessica R AllegrettiDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Colleen R KellyDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Alexander KhorutsDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota.
Byron P VaughnDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Fecal microbiota transplant (FMT) is effective for preventing recurrent Methods: Prospective cohort of patients with rCDI treated with capsule or colonoscopic FMT between 7/1/19 and 11/29/23. This study's primary outcome was 1-month CDI recurrence rates. Predictors of recurrence were assessed using multivariate logistic regression. Results: Overall, 652 individuals received FMT (421 capsule, 223 colonoscopy). Those receiving capsule FMT were older (median 70 vs 59 years, Conclusion: FMT by capsule may be associated with higher CDI recurrence compared to FMT by colonoscopy. This effect appears be greater in individuals older than 65 years, thus highlighting the importance of individualized treatment decisions that balance FMT efficacy with procedural risks. Development of microbiota-based therapeutics for CDI should account for the impact of administration route on efficacy.

Indexed as

Clinical Outcomes ResearchMicrobiota-Based TherapeuticsOlder Adults

Identifiers

PMID42569219
PMCPMC13449360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.